

1            Genetic, Cellular, and Connectomic Characterization of the Adult  
2            Human Brain Regions Commonly Plagued by Glioma

3  
4  
5            Ayan S. Mandal<sup>1\*</sup>, Rafael Romero-Garcia<sup>1</sup>, Michael G. Hart<sup>1,2</sup>, John Suckling<sup>1</sup>

6  
7            <sup>1</sup>Brain Mapping Unit, Department of Psychiatry, University of Cambridge

8  
9            <sup>2</sup>Academic Division of Neurosurgery, Department of Clinical Neurosciences, University of  
10          Cambridge

11  
12  
13          \* Correspondence to: Ayan Mandal, University of Cambridge, Department of Psychiatry,  
14          Herchel Smith Building, Robinson Way, Cambridge, UK CB2 0SZ, Email: [asm82@cam.ac.uk](mailto:asm82@cam.ac.uk)

47 **Abstract**

48  
49 A better understanding of the nonrandom localization patterns of gliomas across the brain could  
50 lend clues to the origins of these types of tumors. Following hypotheses derived from prior  
51 research into neuropsychiatric disease and cancer, gliomas may be expected to localize to brain  
52 regions characterized by hubness, stem-like cells, and transcription of genetic drivers of  
53 gliomagenesis. We combined neuroimaging data from 335 adult patients with high- and low-  
54 grade glioma to form a replicable tumor frequency map. Using this map, we demonstrated that  
55 glioma frequency is elevated in association cortex and correlated with multiple graph-theoretical  
56 metrics of high functional connectedness. Brain regions populated with stem-like cells also  
57 exhibited a high glioma frequency. Furthermore, gliomas were localized to brain regions  
58 enriched with the expression of genes associated with chromatin organization and synaptic  
59 signaling. Finally, a regression model incorporating connectomic, cellular, and genetic factors  
60 explained 58% of the variance in glioma frequency. Our findings illustrate how factors of diverse  
61 scale, from genetic to connectomic, can independently influence the anatomic localization of  
62 oncogenesis.

63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92

## 93 Introduction

94

95 Tumor location represents one of the most important prognostic factors for patients suffering  
96 from primary brain cancers<sup>1,2</sup>, yet little is known about the mechanisms that determine the spatial  
97 distribution of gliomas across the brain.

98 The importance of glioma location for diagnosis and treatment has been recognized since  
99 Percival Bailey and Harvey Cushing's seminal classification of brain tumors in the early 20<sup>th</sup>  
100 century<sup>3</sup>. Whilst brain imaging, primarily MRI, plays an important and routine role in diagnosis  
101 and treatment of brain tumors, there has been little quantitative mapping of their distribution at a  
102 population level. Comprehensive modeling of the key factors involved in determining why  
103 gliomas might be heterogeneously distributed across the brain could shed light on the origins of  
104 these tumors, and consequently inform treatment targets. Three general hypotheses for the spatial  
105 distribution of gliomas include a "connectomic hypothesis", a "cellular hypothesis", and a  
106 "genetic hypothesis", and each is now considered in turn.

107 The connectomic hypothesis posits that highly connected brain regions, known as hubs, are  
108 especially vulnerable to disorders, such as oncogenesis, due to the metabolic costliness of  
109 maintaining many connections<sup>4,5</sup>. The term "connectome" was originally conceived by analogy  
110 to the term "genome", and refers to the collection of all connections, anatomical or functional, in  
111 the brain<sup>6</sup>. The connectome can be defined at the microscale, in which case the connections  
112 represent synaptic links between neurons, or at the macroscale, where the connections can  
113 represent anatomical white matter pathways (structural connectome), or correlations in neuronal  
114 activity (functional connectome) between brain regions<sup>7</sup>. A foundational finding of network  
115 neuroscience is that the connectomes of many different species, across multiple scales, possess a  
116 small-world architecture<sup>8</sup>. In other words, they are composed mostly of short distance  
117 connections between neighboring nodes (brain regions or neurons), but with a few long-distance  
118 connections between distant nodes. The nodes from which originate many of the short and long  
119 distance connections are crucial for efficient communication across the network, and these are  
120 the hubs<sup>9</sup>. Brain hubs are believed to be "costly" due to the metabolic demand of maintaining  
121 many connections<sup>10</sup>, a factor that makes these regions vulnerable to disease<sup>11-14</sup>. Long distance  
122 axonal connections for instance, are physiologically expensive to maintain since proteins in the  
123 neuron's presynaptic terminal must be produced in the nucleus, and thus travel the full distance  
124 of the axon to reach their target. This factor contributes to the vulnerability of upper motor  
125 neurons to degeneration<sup>15</sup>. In a similar way, long distance connections important for the  
126 construction of large-scale cortical networks also pose a challenge for glial cells (in particular,  
127 oligodendrocytes) to support the requisite axonal tracts<sup>16</sup>. Furthermore, brain hubs also receive  
128 many connections, and therefore are populated with many synapses which impose metabolic  
129 demand upon supporting astrocytes<sup>17</sup>. Metabolic demands on the glial cells of hub regions could  
130 contribute to elevated cell turnover, enhancing the likelihood of a cell acquiring an oncogenic  
131 mutation during mitosis<sup>18</sup>. Metabolic stress could also contribute to oncogenesis via enhanced  
132 production of mutagenic reactive oxygen species<sup>19</sup>. For these reasons, one may expect gliomas to  
133 localize to hubs of the brain connectome.

134 With their shared dedifferentiated and proliferative nature, the commonalities between stem  
135 cells and cancer cells have not gone unnoticed among cancer biologists. These commonalities  
136 form the basis of the stem cell hypothesis of cancer, which maintains that cancers tend to  
137 originate from normal stem and stem-like cells in the body<sup>20-22</sup>. When applied to adult glioma,  
138 this hypothesis points to two clear suspects as possible cells-of-origin: neural stem cells (NSCs)

139 and oligodendrocyte precursor cells (OPCs)<sup>21,22</sup>. Neither are randomly distributed throughout the  
140 brain, and therefore their specific localization patterns have been hypothesized to play a role in  
141 determining the nonrandom distribution of gliomas<sup>23,24</sup>. The notion that neural stem cells exist  
142 and continue to proliferate in the adult human brain is relatively new and historically  
143 controversial, but a consensus has arisen that they can be found in at least two locations: the  
144 subgranular zone of the dentate gyrus of the hippocampus, and the subventricular zone<sup>22,25</sup>.  
145 Rodent work has demonstrated that OPCs are widely distributed throughout the mammalian  
146 brain<sup>26</sup>. The patterning of OPCs in the adult human brain is unclear, but could be estimated by  
147 utilizing brain-wide maps of gene expression patterns<sup>27,28</sup>.

148 Adult gliomagenesis is the result of glial cells acquiring a series of somatic mutations which  
149 trigger uncontrollable cell proliferation<sup>30,31</sup>. Recent research has demonstrated that tumor  
150 location is influenced by the genetic aberrations that guide the development of tumors<sup>23,29</sup>.  
151 Gliomas may be expected to localize to brain regions where the genetic risk factors for the  
152 disease are normatively expressed. Furthermore, consequential to the connectomic and cellular  
153 hypotheses, it may be expected that brain regions frequented by glioma are enriched with the  
154 expression of genes associated with cell proliferation or metabolically intensive processes  
155 required for long distance neuronal signaling.

156 In this study, we tested these three hypotheses by examining the connectomic, cellular, and  
157 genetic correlates of brain regions commonly plagued by glioma. We began by deriving a  
158 replicable tumor frequency map from neuroimaging data of 335 adult patients with high- and  
159 low-grade glioma. Using this map, we compared glioma distributions across canonical  
160 subnetworks and correlated them with hub measures calculated from averaged functional  
161 connectivity data from a large number of healthy individuals. Then, we determined if glioma  
162 frequency was elevated among brain regions expected to be enriched with NSCs and OPCs.  
163 Next, we conducted a transcriptomic analysis to find genes with spatial expression patterns that  
164 followed the observed glioma distribution. Finally, we combined all these factors of glioma  
165 distribution into a single regression model to explore the putative inter-relationships of predictors  
166 of glioma frequency.

167

## 168 **Results**

169

### 170 *Anatomical mapping of glioma distribution*

171

172 We initially constructed a map of glioma distribution from aligned masks of tumor volume  
173 across 335 high- and low-grade glioma patients. This tumor frequency map displayed a  
174 hemispherically symmetric, but heterogeneous spatial distribution (Figure 1A). Consistent with  
175 prior reports, gliomas were rare in the occipital lobe, but relatively common in insular cortex  
176 (Figure 1B; Supplementary Table 1). Tumor frequency distributions were replicable across  
177 independent, randomly assigned subsets of half of the images (Groups 1 and 2) with an inter-  
178 regional correlation of  $r=0.83$  (95% CI:  $r=0.70-0.93$ ). Replicability of subsequent analyses was  
179 tested with Group 1 and Group 2 tumor frequency maps (see Supplementary Information).

180 Tumor frequency was compared across canonical, large-scale functional networks and  
181 primary versus association cortex. Association regions responsible for consolidating information  
182 across multiple sensory modalities showed higher tumor prevalence (average voxel: 4.57%) than  
183 visual and somatosensory primary cortices which had the lowest tumor frequency (2.45%),  
184 particularly in the visual cortex (1.56%; Figure 2A and 2B).

185

### 186 ***Gliomas localize to hubs of high connectivity and centrality***

187

188 Graph theory measures were calculated from the mean functional connectome derived from  
189 resting state fMRI scans of over 4000 UK BioBank participants, and then compared with glioma  
190 frequency. The connectome was first organized into seven communities of interconnected nodes  
191 based on their overlap with previously defined large-scale functional networks<sup>32</sup> resulting in a  
192 neat modular organization, with strong connections within modules and sparse connections  
193 between modules (Figure 2C). Graph theory measures of hubness were then calculated,  
194 measuring properties such as connectivity with neighboring nodes, involvement in shortest paths  
195 across the network, connectivity to nodes in different modules, and within-module connectivity  
196 (see *Methods* for how these measures were defined and selected). The inter-regional correlation  
197 between measures of hubness and glioma frequency was tested for significance by comparison to  
198 spatially contiguous null models (Figure 2D).

199 Glioma frequency strongly correlated with the simplest measure of hubness, nodal strength ( $\rho$   
200 = 0.34;  $P_{\text{spin}} = 0.00055$ ), which aggregates the weights of a node's immediate connections.  
201 Glioma frequency was also significantly correlated with betweenness centrality ( $\rho = 0.51$ ;  $P_{\text{spin}} =$   
202 0.0002) and with a measure of connectivity to diverse communities, the participation coefficient  
203 ( $\rho = 0.30$ ;  $P_{\text{spin}} = 0.011$ ). Connectivity within a community, measured by Z-score modularity, did  
204 not relate with glioma frequency ( $\rho = 0.062$ ;  $P_{\text{spin}} = 0.21$ ; Figure 2D). This profile of connectivity  
205 measures was most consistent with that of connector hubs that link together multiple sub-  
206 networks.

207

### 208 ***Glioma frequency is elevated in areas with populations of stem-like brain cells***

209

210 We tested the hypothesis that brain regions enriched with NSCs were more likely to coincide  
211 with loci of high frequency of gliomas. Mean tumor frequency was calculated from the  
212 hippocampus and the caudate (Figure 3A), regions which best approximate the locations of the  
213 only known sources of NSCs in the adult human brain. Tumor frequency across bilateral  
214 hippocampus and caudate were averaged, and compared against a null distribution of 10000  
215 different pairs of randomly selected parcels within our 334-region parcellation scheme. Glioma  
216 frequency was observed to be significantly higher in these two regions compared to the null  
217 distribution ( $p = 0.0315$ ; Figure 3B).

218 Next, we tested the spatial correspondence of glioma distribution with the patterning of OPCs,  
219 which are also hypothesized to be cells-of-origin for glioma. OPC distribution was estimated  
220 from the expression of genetic markers of OPC identity using post-mortem the microarray data  
221 of the Allen Human Brain Atlas (AHBA; [www.brain-map.org](http://www.brain-map.org)). The list of genetic markers for  
222 OPC's co-expressed significantly (Figure 3C) confirmed that median expression across this gene  
223 list represents a spatially specific phenotype. This estimate of OPC patterning correlated  
224 significantly with glioma frequency (Figure 3D;  $\rho = 0.45$ ;  $P_{\text{spin}} = 0.0001$ ).

225

### 226 ***Transcriptomic correlates of glioma frequency***

227

228 We used partial least squares (PLS) regression to relate the spatial transcription patterns of  
229 20647 genes with tumor frequency at 2748 cortical and subcortical locations where gene  
230 expression was assessed in postmortem adult human brain tissue (Figure 4A,B). The first two

231 components of the PLS (PLS1 and PLS2) explained 19% and 18% of the tumor frequency  
232 variance, respectively (Supplementary Figure 3A), more than expected by chance (Permutation  
233 test;  $p < 0.001$ ; Supplementary Figure 3B).

234 Bootstrapping was performed on PLS weights resulting in Z statistics for each gene  
235 corresponding to the PLS1 and PLS2 ranking (Supplementary Figure 3C). The ranked gene lists  
236 were entered into a gene ontology (GO; <http://cbl-gorilla.cs.technion.ac.il/>). Genes  
237 corresponding to PLS1 were related to biological processes such as chromatin organization,  
238 endosomal transport, and G0 to G1 transition. Genes corresponding to PLS2 were related to a  
239 broad set of metabolic processes along with many components of synaptic transmission (Figure  
240 4C). PLS1 was also found to be significantly enriched for genetic drivers of gliomagenesis ( $p =$   
241  $0.026$ ; Figure 4D). PLS2 was not significantly enriched for this set of genes ( $p = 0.75$ ).

242 PLS1 was more highly loaded onto the subcortex relative to the cortex (Figure 4E). PLS  
243 loadings for each AHBA sample were mapped to their nearest brain region for visualization on  
244 the cortical surface (Figure 4F).

245

### 246 *Connectomic, cellular, and genetic contributions to glioma frequency are independent*

247

248 Finally, we sought to reveal the interrelations between the connectomic, cellular, and genetic  
249 contributions to glioma distribution uncovered in the study. A multiple linear regression model  
250 was constructed, with factors of nodal strength, OPC distribution, PLS1 loadings, and PLS2  
251 loadings (Figure 5A). NSC distribution was not included in the model because this measure  
252 could not be quantified at each brain parcel. First, we tested a model to determine if there were  
253 interaction effects between connectomic (nodal strength), cellular (OPC distribution), and  
254 genetic (PLS1 and PLS2 loadings) factors. None of the interaction effects were significant. The  
255 model without interaction effects explained approximately 58% of the variance in glioma  
256 frequency ( $F(4,162) = 59.3$ ;  $p = 9.37 \times 10^{-31}$ ; Adjusted  $R^2 = 0.584$ ; Figure 5B,C). All individual  
257 factors significantly predicted tumor frequency variance (Table 1; Figure 5D). Because of the  
258 unequal mapping of AHBA samples to cortical versus subcortical regions, the PLS2 component,  
259 which is more highly represented across cortex, explained more of the variance in tumor  
260 frequency than PLS1 once projected onto the anatomy. It is also worth noting that the amount of  
261 variance explained by the PLS factors was inflated by construction, due to the large number of  
262 input variables and the design of the technique which results in maximizing covariance<sup>33</sup>.

263

### 264 **Discussion**

265

266 In this study, we examined the network, cellular, and transcriptomic correlates of brain  
267 regions commonly frequented by glioma to test specific hypotheses regarding gliomagenesis. We  
268 found that gliomas were most common in association cortex and connector hub regions. Elevated  
269 glioma frequency was observed in brain regions expected to be populated by NSCs and OPCs.  
270 Finally, we determined that glioma distribution correlated with the spatial transcription patterns  
271 of genes related to metabolic activity, synaptic signaling, and gliomagenesis. These findings  
272 support the predictions of network neuroscience and cancer theory, and establish links between  
273 concepts from these two frameworks to characterize the spatial distribution of adult gliomas.

274 An extensive body of work has demonstrated the utility of network models in predicting the  
275 spread of disease<sup>34-36</sup> as well as the vulnerability of particular brain regions to disease<sup>11,12,14</sup>. In  
276 this work, we used network models to demonstrate for the first time that functional hub regions



277 of the brain are vulnerable to the concentration of gliomas. In particular, gliomas appear to  
278 localize to brain regions expected to play the role of connector hubs, nodes that link diverse  
279 cognitive subsystems with one another, as opposed to provincial hubs, which integrate  
280 communication within their own subsystems<sup>9</sup>. This suggests that the brain regions which  
281 facilitate long distance connections across the cortex are especially vulnerable to oncogenesis,  
282 consistent with our hypothesis that the high metabolic cost of such connections influences  
283 glioma risk<sup>10</sup>. Alternatively, the results can be interpreted as reflecting a higher likelihood for  
284 tumor infiltration of hub regions. Gliomas are known to migrate throughout the brain via blood  
285 vessels and white matter tracts, which contributes to the poor prognosis of glioblastoma  
286 multiforme. Here we consider only the location of the tumor during the pre-operative scan,  
287 which could represent either the tumor origin, or to where it spread during the progression of the  
288 disease. Although networks were constructed from functional MRI and not white matter tracts  
289 along which tumors are known to infiltrate<sup>37</sup>, recent work on activity-dependent glioma  
290 migration suggests that tumors could preferentially invade functional hubs<sup>38</sup>. Due to their high  
291 centrality, hubs are, by definition, likely to be encountered during random walks within a  
292 network.

293 Ever since its conception, association cortex has been thought to play an important role in  
294 integrating information across sensory modalities and in the etiology of neurological  
295 syndromes<sup>39</sup>. The localization of gliomas to association cortex provides support for the  
296 “tethering hypothesis”, or the notion that the association cortices lack developmental stability  
297 compared to the more evolutionarily conserved primary cortices, introducing vulnerability for  
298 neuropsychiatric conditions<sup>10,40</sup>. Past work has implicated the tethering hypothesis within the  
299 context of psychiatric diseases such as autism and schizophrenia<sup>41,42</sup>. The application of this idea  
300 to gliomagenesis suggests that the extensive scaling of association cortex during hominid  
301 evolution, an event purportedly responsible for human-unique cognition<sup>40</sup>, may also have  
302 introduced risk for brain cancer. This idea is consistent with the observation that genes likely  
303 involved in cortical scaling (e.g. neurodevelopmental genes guiding proliferation of neural and  
304 glial cells) are affected in glioma<sup>43</sup>.

305 Early work on gliomagenesis hypothesized that mature glial cells were the cells-of-origin for  
306 adult glioma. However, it was soon recognized that the cell-of-origin most likely maintains  
307 pluripotency after development, since such cells require fewer mutations to become cancerous<sup>22</sup>.  
308 Following recent evidence of NSCs in the subventricular zone and dentate gyrus of the  
309 hippocampus of adults, there is an emerging consensus that stem-like cells (including OPCs)  
310 could be the cells-of-origin for glioma<sup>21,22</sup>. Recent work has provided strong evidence that some  
311 IDH-wildtype glioblastomas originate from stem cells in the subventricular zone<sup>44</sup>. Lee and  
312 colleagues demonstrated that for a majority of their glioblastoma patients, the unaffected  
313 subventricular zone carried low-level driver mutations, which were present to greater extent in  
314 the tumor. Our findings complement this research by establishing that gliomas in general are  
315 more highly concentrated in regions enriched with NSCs.

316 OPCs have also been hypothesized to represent cells-of-origin for glioma. Evidence for this  
317 idea comes from studies demonstrating that some gliomas express OPC genetic markers<sup>45,46</sup>, and  
318 that OPCs can be experimentally manipulated into becoming cancer stem cells<sup>47,48</sup>. OPCs  
319 comprise the majority of dividing cells in the adult brain and are distributed broadly throughout  
320 the subventricular zone, white matter, and gray matter<sup>21,26</sup>. We estimated this distribution by  
321 quantifying normative expression levels of OPC genetic markers across the human brain, and  
322 found that it significantly correlated with glioma frequency. While this result aligns nicely with

323 prior work, estimates of OPC distribution relied on combining data from two independent  
324 transcriptomic studies of post-mortem human brains<sup>27,49</sup>. While this approach has been validated  
325 for determining the brain-wide distribution of other canonical cell types<sup>28</sup>, our result should be  
326 confirmed once reliable estimates of OPC patterning become available.

327 Normal cells can become malignant through a series of somatic mutations which disable  
328 tumor suppressors and activate drivers of cell proliferation<sup>50</sup>. To determine the genetic alterations  
329 involved in oncogenesis, much research has focused on identifying molecular genetic differences  
330 between tumor cells and matched healthy tissue<sup>51,52</sup>. Here, we took an alternative approach and  
331 investigated transcriptomic differences between healthy regions where tumors tend to occur  
332 versus healthy regions where tumors are uncommon. As expected, this approach recapitulated  
333 prior research into glioma genetics, in that genes which drive gliomagenesis appeared to be  
334 upregulated among the healthy transcriptomic correlates of glioma distribution. Gene ontology  
335 revealed that the genes driving PLS1 (the component responsible for most of the covariance  
336 between transcription and glioma distribution) were most strongly associated with chromatin  
337 organization, a process perturbed by IDH mutations and critically involved in the pathogenesis of  
338 glioma<sup>31,53</sup>. In addition, our approach also revealed novel findings, such as the carcinogenic  
339 vulnerability of healthy brain regions enriched with genes coordinating synaptic signaling and  
340 metabolic activity. These findings complement our connectomic results, providing more  
341 evidence for the idea that metabolically demanding brain regions crucial for brain-wide  
342 communication are susceptible to oncogenesis.

343 The goal of this study was to examine brain regions generally implicated in adult glioma.  
344 However, adult glioma is a heterogeneous phenomenon, comprising tumors of differing genetic  
345 etiologies and morphologies. It is known that different types of glioma tend to localize to  
346 different brain regions<sup>4,23,24,29</sup>. Therefore, the exact composition of patients (e.g. proportion of  
347 high-grade to low-grade glioma patients) within our sample could influence the results. To  
348 address this concern, we replicated our results with subgroups of varying proportions of high-  
349 grade to low-grade glioma patients and demonstrated that our results are robust to changes to the  
350 composition of the sample. However, we did not have access to the molecular genetic  
351 characterization of the tumors in our sample, limiting our ability to determine the effect of tumor  
352 genotype on the results. Examining glioma subtypes separately could illuminate the network,  
353 cellular, and transcriptomic correlates which distinguish localization patterns of different types of  
354 glioma. Such work could be useful for developing scientifically informed priors for tumor  
355 diagnosis before biopsy, so this question is of both scientific and clinical interest.

356

## 357 **Conclusion**

358

359 Gaining a better understanding of the mechanisms driving glioma localization patterns could  
360 provide a more detailed account of the etiology of the disease and consequently inform treatment  
361 targets. We demonstrated that glioma distribution can in part be explained by functional hubness,  
362 distribution of stem-like cells, and transcription patterns of genetic determinants of glioma.  
363 These results add to previous literature reporting the vulnerability of hub regions to neurological  
364 disease<sup>10,11</sup>, as well as providing support for cancer stem cell theories of glioma<sup>20,22,25</sup>. Our  
365 findings highlight the importance of bridging diverse scales of biological organization in the  
366 study of oncogenesis.

367

## 368 **Methods**



369

### 370 *Tumor Frequency Map*

371

372 Neuroimaging data of patients with low and high grade gliomas were accessed from the  
373 Multimodal Brain Tumor Image Segmentation Challenge 2019 (BraTS:  
374 <http://braintumorsegmentation.org>)<sup>54-56</sup>. T1-weighted contrast-enhanced scans from 259 patients  
375 with high-grade glioma and 76 patients with low-grade glioma were segmented by board-  
376 certified neuroradiologists, denoting voxels that constituted gadolinium enhancing tumor, non-  
377 enhancing core, and peritumoral edema<sup>55</sup>. Segmentation was informed by multimodal imaging,  
378 including T1-weighted, post-contrast T1-weighted, T2-weighted, and T2 Fluid Inversion  
379 Attenuated Recovery (T2-FLAIR) scans. Scans were acquired at nineteen different institutions  
380 (<https://www.med.upenn.edu/cbica/brats2019/people.html>) with different sequences and  
381 protocols. These data were pre-processed through the same pipeline, undergoing linear  
382 registration to a common template (SRI24)<sup>57</sup>, resampling at 1mm<sup>3</sup> isotropic resolution, and  
383 removing non-brain tissues from the image<sup>56</sup>.

384 The minimally pre-processed images were downloaded from the Center for Biomedical Image  
385 Computing & Analytics Image Processing Portal (CBICA IPP). Images from each patient were  
386 nonlinearly warped to a common template<sup>57</sup> using Advanced Normalization Tools software  
387 (ANTS)<sup>58</sup>, with cost function masking of abnormal brain tissue. The registered masks comprising  
388 the gadolinium enhancing tumor and non-enhancing core were taken to represent (and hereafter  
389 will be referred to as) the tumor mask.

390 Tumor masks were concatenated across all 335 patients to create a tumor frequency map,  
391 where the value at each voxel denotes the percentage of tumors of the sample that overlapped  
392 with that voxel (Figure 1A). Smoothing with a 2 mm full width half maximum (FWHM)  
393 Gaussian kernel was applied to the map. An unsmoothed version of this map is shown in  
394 Supplementary Information (Supplementary Figure 1). To match genetic data for which most of  
395 the samples come from one hemisphere<sup>27</sup>, we mirrored the tumor frequency map to the left  
396 hemisphere for the following analyses. Given the large sample size and concordance with other  
397 studies<sup>4,59</sup>, this tumor frequency map was interpreted as representing general glioma spatial  
398 distribution.

399

### 400 *Tumor Frequency Parcellation*

401

402 To quantify tumor frequency by common anatomic subdivisions, we applied to the tumor  
403 frequency map an in-house 334 region (with 167 left hemisphere regions) parcellation covering  
404 16 subcortical and 318 neocortical areas. This symmetric parcellation was created by applying a  
405 back-tracking algorithm that restricts the parcel size to 500 mm<sup>2</sup> with the Desikan-Killany atlas  
406 boundaries as starting points<sup>60</sup>. Although this parcellation was gray matter based, parcels were  
407 extended 4 mm into the white matter to capture tumor frequency in adjacent white matter  
408 regions. Tumor frequency for a parcel was calculated by averaging the voxel value (representing  
409 percent tumor overlap) of the mirrored tumor frequency map within each left hemisphere parcel.

410

### 411 *Internal Replicability*

412

413 The internal replicability of our tumor frequency map was tested by correlating tumor  
414 frequency maps derived from randomly assigned, nonoverlapping cohorts of 168 and 167  
415 patients (Groups 1 and 2).

416 Simultaneously, we tested the generalizability of our results to groups constituted of differing  
417 proportions of low grade versus high grade gliomas. The first group (Group 1) had a 50% higher  
418 proportion of low grade gliomas (~34%) as the full cohort (~23%), whereas the second group  
419 (Group 2) was constituted of a 50% lower proportion of low grade glioma patients (~11%),  
420 These tumor frequency maps were constructed with the same processing as that with the full  
421 sample (smoothing, mirroring to the left hemisphere, and parcellation). A 95% confidence  
422 interval (CI) for the inter-parcel correlation between Group 1 and Group 2 was determined by  
423 constructing a distribution of 100 correlation coefficients where different patients were selected  
424 for each group.

425

#### 426 *Statistical Inference of Brain Map Correspondence*

427

428 Several analyses in this study involved investigating the spatial correspondence between  
429 different imaging derived measures. In general, this was accomplished by calculating the  
430 measures at each parcel in the common parcellation scheme, then correlating these measures  
431 across parcels for hypothesis testing. However, since the spatial resolution (and thus the number  
432 of parcels) of any parcellation scheme is essentially arbitrary, the actual degrees of freedom  
433 cannot be estimated. This is aggravated by the spatial autocorrelation of measures among  
434 neighboring parcels that violates the assumption of independent observations. This issue has  
435 been addressed in past studies by use of what is termed a “spin test”<sup>61–64</sup>. The spin test procedure  
436 is described in more detail in the Supplementary Information. In general, it involves comparing  
437 the observed inter-parcel correlation between maps of two measures with a distribution of  
438 correlations calculated after one of these maps has been spatially permuted in a way that  
439 preserves contiguity among parcels.

440

#### 441 *Comparison of Glioma Frequency across Canonical Subnetworks*

442

443 One question of interest was whether gliomas localized to particular brain subnetworks.  
444 Seven canonical subnetworks of the brain  
445 ([https://surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation\\_Yeo2011](https://surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation_Yeo2011))<sup>32</sup> were mapped onto  
446 the tumor frequency map. Violin plots were constructed to compare the distribution of nonzero  
447 tumor frequency values between voxels belonging to differing canonical subnetworks.

448

#### 449 *Functional Connectome*

450

451 Glioma frequency was compared to regional connectivity (hubness) as quantified by graph  
452 theory metrics applied to the functional connectome derived from resting state fMRI data<sup>65,66</sup>  
453 from over 4000 UK BioBank participants (age range 44-78 years; 53% female). The publicly  
454 available “dense voxel-wise connectome” of the first UK BioBank cohort  
455 (<https://www.fmrib.ox.ac.uk/ukbiobank/>) corresponds to a 4-D image, where each voxel consists  
456 of 1200 principal components derived from a group-level PCA<sup>67</sup>. A correlation between voxels  
457 across components gives a close, memory efficient approximation to the correlation of BOLD  
458 signal calculated across concatenated timepoints from all individual participants<sup>67</sup>. The

459 aforementioned 334 region in-house parcellation, covering both subcortical and cortical regions,  
460 was applied to the voxel-wise connectome. PCA loadings for voxels within each parcel (i.e.  
461 region) were averaged (analogous to a mean timeseries) and correlated between parcels to  
462 produce the weights of a graph (Figure 2C). Diagonal elements and negative correlations were  
463 set to zero. The same parcellation was also applied to the tumor frequency map to quantify tumor  
464 frequency within each parcel. Tumor frequency for a parcel represented the average percentage  
465 of lesion overlap of voxels within that parcel. The common parcellation allowed for comparison  
466 between measures of tumor frequency and functional hubness.

467

### 468 *Graph Theory Metrics of Hubness*

469

470 Once the weighted healthy connectome had been constructed, we calculated graph theoretical  
471 metrics of hubness using the Brain Connectivity Toolbox<sup>68</sup>. In this graph theoretical approach to  
472 neuroimaging data, parcels of the brain are conceived as “nodes”, whereas correlations in  
473 functional activity between parcels are conceived as the weights of connections between the  
474 nodes. Hub metrics derived included: nodal strength (sum of all weighted connections for a  
475 particular node), betweenness centrality (fraction of all shortest paths in a network that pass  
476 through a certain node), clustering coefficient (average weighted connections of triangular  
477 subgraphs associated with a node), local efficiency (inverse of the average shortest path length  
478 between a node and every other node), eigenvector centrality (the extent to which a given brain  
479 region connects to other regions with higher centrality), participation coefficient (the strength of  
480 connections outside of a node’s given module relative to connections within that node’s module),  
481 and within-module degree z-score (nodal strength of a node within its module, compared to  
482 within-module nodal strengths of each other node in the module). To reduce the impact of  
483 community affiliation on participation coefficient and within-module degree z-score, community  
484 affiliations were designated based on the maximum spatial overlap of each node with one of the  
485 seven canonical subnetworks<sup>32</sup>.

486 Hub measures were calculated for each of the 334 nodes of the functional connectome.  
487 Measures from homotopic nodes were then averaged together, resulting in 167 observations for  
488 each subcortical and cortical parcel per hub metric. Many of the hub measures were observed to  
489 have a high correlation with nodal strength. Therefore, we screened out hub measures which had  
490 a Spearman’s correlation of  $\rho > 0.95$  with nodal strength. This led to the removal of clustering  
491 coefficient, local efficiency, and eigenvector centrality. While this threshold is arbitrary, the  
492 same result was reached with thresholds ranging from 0.65 to 0.99 (Supplementary Figure 2).  
493 Spearman’s correlations were calculated between the remaining hub metrics and tumor  
494 frequency and were assessed for significance by comparison to spatially contiguous null models,  
495 via the spin test (see Supplementary Information).

496

### 497 *Cellular Correlates of Tumor Frequency*

498

499 To determine whether tumors were more common in regions enriched for NSCs, we assessed  
500 tumor frequency within the two parcels of our 334 region parcellation which most closely  
501 aligned with the subventricular zone and the dentate gyrus: the caudate and the hippocampus.  
502 The average tumor frequency between these two parcels was compared to average tumor  
503 frequency between 10000 random pairs of parcels.

504 To determine if tumors were more common in regions enriched for OPCs, we compared  
505 tumor frequency to an expression map of OPC cell class. This expression map was estimated by  
506 assessing transcriptional enrichment of OPC genetic markers using a procedure analogous to that  
507 previously described<sup>28</sup>. An OPC gene set was derived from a single cell RNA sequencing study  
508 performed on adult postmortem cortical tissue<sup>49</sup> that determined genes with transcription patterns  
509 distinguishing cells by canonical cell types, including excitatory and inhibitory neurons,  
510 astrocytes, oligodendrocytes, and OPCs. The set of 132 genes that distinguished OPCs from  
511 other canonical cell classes across the cortex was downloaded from previously published  
512 material<sup>49</sup>. Next, we determined parcels where the OPC gene set was upregulated in the adult  
513 brain using the publicly available Allen Human Brain Atlas (AHBA)<sup>27</sup>. The Allen Human Brain  
514 Atlas catalogues postmortem gene expression from six individuals (ages 24 to 57 years old; five  
515 males and one female) at a variety of brain locations. Transcription patterns of 20,647 genes  
516 were aligned to the 159 left hemisphere cortical regions in our parcellation, using prior  
517 methods<sup>69,70</sup> with code available for download  
518 ([https://github.com/RafaelRomeroGarcia/geneExpression\\_Repository](https://github.com/RafaelRomeroGarcia/geneExpression_Repository)). The resulting 159 x  
519 20,647 regional gene expression matrix was z-scored by parcel. Because the OPC gene set was  
520 derived from sequencing performed on cortical brain tissue, we decided to exclude subcortical  
521 regions from this part of the analysis.

522 First, 13 genes in the OPC gene set were not matched to any AHBA probe and were  
523 consequently excluded from the analysis. We evaluated the spatial specificity of the remaining  
524 119 OPC genes by comparing their co-expression pattern with 1000 identically-sized sets of  
525 randomly chosen genes. OPC genes were filtered out that did not share a positive co-expression  
526 pattern with the overall group of genes. Concretely, the 24 genes which had, on average,  
527 negative correlations with other genes in the set were removed from the OPC gene set. We  
528 estimated OPC distribution by calculating the median regional enrichment of the filtered OPC  
529 gene set across cortical parcels. OPC distribution across 159 cortical parcels was then correlated  
530 with tumor frequency and tested for significance using the spin test.

531

### 532 *Aligning Tumor Frequency Map with the Allen Human Brain Atlas*

533

534 Next, we compared tumor frequency with postmortem gene expression from the Allen Human  
535 Brain Atlas (<http://human.brain-map.org/>)<sup>27</sup>. Pre-processing of the AHBA data followed a  
536 similar pipeline to previous work from our group<sup>69,70</sup> and is described in more detail in the  
537 Supplementary Information. Transcription levels for 20647 genes across 2748 sample locations  
538 were related to tumor frequency at each sample location using partial least squares (PLS)  
539 regression. Tumor frequency values were aligned with sample locations by warping the non-  
540 smoothed, non-mirrored tumor frequency map into the standard stereotactic space of the  
541 Montreal Neurological Institute (MNI), a standard brain template for which the locations of the  
542 AHBA microarray samples are known. Once in MNI space, a 2 mm FWHM smoothing kernel  
543 was applied to the map and the map was mirrored to the left hemisphere. Sample locations from  
544 the AHBA that were located in the right hemisphere were also mirrored to their homotopic voxel  
545 in the left hemisphere. This alignment resulted in a 2748 (samples) by 20647 (genes) expression  
546 matrix and in a vector of 2748 elements representing tumor frequency values matched to each  
547 sample's MNI coordinates (Figure 4 A,B). Tumor frequency values were square rooted to reduce  
548 the skewness of the tumor frequency distribution (Figure 1B). Gene expression values were Z

549 scored for each gene. To test the robustness of the findings, the analyses below were repeated  
550 using tumor frequency maps derived from Group 1 and Group 2.

551

### 552 *Transcriptomic Correlates of Tumor Frequency*

553

554 PLS regression was used to relate spatial transcription patterns of 20647 genes with the  
555 spatial distribution of glioma. PLS regression involves projecting a predictor (X) and a response  
556 (y) matrix into a space where linear combinations of X explain the maximum amount of variance  
557 in y. We chose to focus on the first two components from PLS (PLS 1 and PLS2) as the  
558 subsequent components explained a proportion of variance indistinguishable from one another  
559 (Supplementary Figure 3A). Statistical significance of the PLS model was tested via permutation  
560 testing, by comparing the percent variance explained in the original model to a distribution of  
561 1000 models where the sample labels mapping X to y were randomly shuffled. Significance of  
562 each PLS coefficient was tested via bootstrapping with 1000 iterations, resulting in two Z  
563 statistics for each gene, one for the first PLS component and another for the second PLS  
564 component. Genes were ranked by their Z statistics and entered into gene ontology analyses in  
565 GOrilla (<http://cbl-gorilla.cs.technion.ac.il/>), resulting in a hierarchy of biological terms  
566 associated with each PLS component, visualized using Revigo<sup>71</sup>. To ensure a data-driven  
567 approach, genes with Z statistic values that did not meet the Bonferroni-corrected significance  
568 threshold were not excluded from the gene lists.

569

### 570 *Relating PLS Components to Glioma-related Genes*

571

572 We sought to determine whether either of our PLS components were enriched for genes that  
573 are dysregulated in glioma. We collected a list of 20 genes from a recent review<sup>30</sup> (listed in the  
574 Supplementary Information) that are known to be either mutated, amplified, or lost in specific  
575 subtypes of glioma. Four of these genes (*PDGFRA1*, *RIK*, *RIS*, and *PI3K*) were not matched to  
576 any AHBA probe and were accordingly excluded from the analysis.

577 Similar to the OPC gene list preprocessing, we first confirmed that these genes co-expressed  
578 significantly (compared to 10,000 identically sized sets of genes). Next, we filtered out genes  
579 with differing co-expression patterns from the group (denoted by negative correlations, on  
580 average, with other genes in the set), leading to the exclusion of three genes (*IDH2*, *MYCN*, and  
581 *CIC*). The median rank of the final list of 13 genes was determined among the first and second  
582 PLS components and assessed for significance by comparison to median ranks expected by  
583 chance.

584

### 585 *Visualization of PLS Components*

586

587 We were interested in the locations of the samples which drove each PLS component. First,  
588 PLS1 and PLS2 loadings were plotted and colored based of the affiliation of the sample with  
589 cortex or subcortex. To determine how PLS1 and PLS2 loadings mapped onto cortex, we  
590 assigned samples to parcels via a nearest neighbor mapping. Then, the PLS loading of a parcel  
591 was represented as the median PLS loading across samples assigned to that parcel. Two parcels  
592 were assigned zero samples from nearest neighbor mapping, and these parcels were assigned the  
593 mean loading of the group. More samples were mapped to each subcortical parcel (N=8;  
594 mean=78.9; SD=52.1) compared to cortical parcels (N=159; mean=13.3; SD=12.5).



595  
596 *Multivariate Model Combining Connectomic, Cellular, and Genetic Contributions to Tumor*  
597 *Frequency*  
598

599 To determine how different measures of biological contributions to glioma risk interrelated,  
600 we developed a multiple linear regression model combining each of the factors we found to be  
601 associated with tumor frequency. The model included nodal strength, OPC distribution, PLS1  
602 loadings, and PLS2 loadings. Each of these measures was represented as a 167-dimensional  
603 vector, with a value ascribed to each parcel within our parcellation scheme. The dependent  
604 variable for the model was the square root of average tumor frequency within each parcel. The  
605 square root of tumor frequency was taken to address the skewness of the original tumor  
606 frequency values (Figure 1B). The dependent variable and each of the predictors were Z scored,  
607 and zeros were assigned to parcels for which no value could be appropriately calculated (e.g.  
608 subcortical parcels for OPC distribution, and parcels mapped to zero samples for PLS1 and PLS2  
609 loadings).

610 First, we constructed a model to determine whether there were any two-way interaction  
611 effects between the different scales of biological factors. Nodal strength represented  
612 “connectomic factors”, OPC distribution represented “cellular factors”, and PLS1 and PLS2  
613 loadings represented “genetic factors”. This model had the following form:

614  
615 
$$\text{tumor frequency} = b_0 + b_1 * \text{strength} + b_2 * \text{strength|OPC} + b_3 * \text{strength|PLS1} + b_4 * \text{strength|PLS2} + b_5 * \text{strength|OPC|PLS1} + b_6 * \text{strength|OPC|PLS2} + b_7 * \text{strength|PLS1} + b_8 * \text{strength|PLS2} + b_9 * \text{strength|OPC|PLS1} + b_{10} * \text{strength|OPC|PLS2} + \varepsilon$$
  
616  
617  
618

619 This model revealed no significant interactions effects between different biological factors.  
620 Therefore, we constructed a second model with no interaction terms, of the form:

621  
622 
$$\text{tumor frequency} = b_0 + b_1 * \text{strength} + b_2 * \text{OPC} + b_3 * \text{PLS1} + b_4 * \text{PLS2} + \varepsilon$$
  
623

624 After determining the percentage of explained variance in tumor frequency from these  
625 predictors, we explored the individual contribution of each variable by calculating the square of  
626 the partial correlation between that variable and tumor frequency. Significance of the explained  
627 variance was assessed by comparison to the distribution of explained variances between the  
628 variable and 10000 permuted, spatially contiguous, null models of tumor frequency.

629 **Acknowledgements**  
630

631 We thank the Brain Tumor Segmentation Challenge (BraTS) for access to the MRI scans and  
632 lesion masks used in the study, as well as the patients who participated in that project. This  
633 research also relied on imaging data from UK BioBank and genetic data from the Allen Brain  
634 Institute. A.S.M. was funded by a Gates Cambridge Scholarship. R.R.G. was funded by a  
635 Guarantors of Brain fellowship. Data were stored and processed on the High Performance Hub  
636 for Clinical Informatics (HPHI) platform, funded by a Medical Research Council (MRC)  
637 infrastructure award (MR/M009041/1).

638  
639 **Author Contributions**

640  
641 A.S.M., R.R.G., and M.G.H conceived of the research idea. A.S.M. performed the analyses, with  
642 R.R.G., M.G.H, and J.S. supervising the work. A.S.M. drafted the article. All authors discussed  
643 the results and commented on the manuscript.

644  
645 **Competing Interests**

646  
647 None.

648  
649 **Ethics Statement**

650  
651 The research described in this manuscript used anonymized data made publicly available via the  
652 International Brain Tumor Segmentation (BraTS) challenge. All other data considered here had  
653 similarly been anonymized before being made publicly accessible.

654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685

686 **References**

687

- 688 1. Jeremic, B. *et al.* Influence of extent of surgery and tumor location on treatment outcome  
689 of patients with glioblastoma multiforme treated with combined modality approach. *J.*  
690 *Neurooncol.* (1994). doi:10.1007/BF01052902
- 691 2. Sagberg, L. M. *et al.* Brain atlas for assessing the impact of tumor location on  
692 perioperative quality of life in patients with high-grade glioma: A prospective population-  
693 based cohort study. *NeuroImage Clin.* (2019). doi:10.1016/j.nicl.2019.101658
- 694 3. Bailey, P. & Cushing, H. A Classification of the Tumors of the Glioma Group on a  
695 Histogenetic Basis with a Correlated Study of Prognosis. *Arch. Neurol. Psychiatry* (1926).  
696 doi:10.1001/jama.1926.02680040056039
- 697 4. Duffau, H. & Capelle, L. Preferential brain locations of low-grade gliomas. *Cancer*  
698 (2004). doi:10.1002/cncr.20297
- 699 5. Duffau, H. *Diffuse low-grade gliomas in adults. Diffuse Low-Grade Gliomas in Adults*  
700 (2017). doi:10.1007/978-3-319-55466-2
- 701 6. Seung, S. *Connectome: how the brain's wiring makes us who we are.* (Houghton Mifflin  
702 Harcourt, 2012).
- 703 7. Bullmore, E. & Sporns, O. Complex brain networks: Graph theoretical analysis of  
704 structural and functional systems. *Nature Reviews Neuroscience* (2009).  
705 doi:10.1038/nrn2575
- 706 8. Bassett, D. S. & Bullmore, E. Small-world brain networks. *Neuroscientist* (2006).  
707 doi:10.1177/1073858406293182
- 708 9. van den Heuvel, M. P. & Sporns, O. Network hubs in the human brain. *Trends in*  
709 *Cognitive Sciences* (2013). doi:10.1016/j.tics.2013.09.012
- 710 10. Bullmore, E. & Sporns, O. The economy of brain network organization. *Nature Reviews*  
711 *Neuroscience* (2012). doi:10.1038/nrn3214
- 712 11. Crossley, N. A. *et al.* The hubs of the human connectome are generally implicated in the  
713 anatomy of brain disorders. *Brain* (2014). doi:10.1093/brain/awu132
- 714 12. Warren, D. E. *et al.* Network measures predict neuropsychological outcome after brain  
715 injury. *Proc. Natl. Acad. Sci. U. S. A.* (2014). doi:10.1073/pnas.1322173111
- 716 13. Aerts, H., Fias, W., Caeyenberghs, K. & Marinazzo, D. Brain networks under attack:  
717 Robustness properties and the impact of lesions. *Brain* (2016). doi:10.1093/brain/aww194
- 718 14. Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D.  
719 Neurodegenerative Diseases Target Large-Scale Human Brain Networks. *Neuron* (2009).  
720 doi:10.1016/j.neuron.2009.03.024
- 721 15. Nijssen, J., Comley, L. H. & Hedlund, E. Motor neuron vulnerability and resistance in  
722 amyotrophic lateral sclerosis. *Acta Neuropathologica* (2017). doi:10.1007/s00401-017-  
723 1708-8
- 724 16. Buzsáki, G., Geisler, C., Henze, D. A. & Wang, X. J. Interneuron Diversity series: Circuit  
725 complexity and axon wiring economy of cortical interneurons. *Trends in Neurosciences*  
726 (2004). doi:10.1016/j.tins.2004.02.007
- 727 17. Magistretti, P. J. & Allaman, I. A Cellular Perspective on Brain Energy Metabolism and  
728 Functional Imaging. *Neuron* (2015). doi:10.1016/j.neuron.2015.03.035
- 729 18. Wodarz, D. Effect of stem cell turnover rates on protection against cancer and aging. *J.*  
730 *Theor. Biol.* (2007). doi:10.1016/j.jtbi.2006.10.013
- 731 19. Rinaldi, M. *et al.* ROS and brain gliomas: An overview of potential and innovative

- 732 therapeutic strategies. *International Journal of Molecular Sciences* (2016).  
733 doi:10.3390/ijms17060984
- 734 20. Visvader, J. E. Cells of origin in cancer. *Nature* (2011). doi:10.1038/nature09781
- 735 21. Jiang, Y. & Uhrbom, L. On the origin of glioma. *Ups. J. Med. Sci.* (2012).  
736 doi:10.3109/03009734.2012.658976
- 737 22. Sanai, N., Alvarez-Buylla, A. & Berger, M. S. Neural Stem Cells and the Origin of  
738 Gliomas. *N. Engl. J. Med.* (2005). doi:10.1056/nejmra043666
- 739 23. Zlatescu, M. C. *et al.* Tumor location and growth pattern correlate with genetic signature  
740 in oligodendroglial neoplasms. *Cancer Res.* (2001).
- 741 24. Mueller, W. *et al.* Genetic signature of oligoastrocytomas correlates with tumor location  
742 and denotes distinct molecular subsets. *Am. J. Pathol.* (2002). doi:10.1016/S0002-  
743 9440(10)64183-1
- 744 25. Ma, D. K., Bonaguidi, M. A., Ming, G. L. & Song, H. Adult neural stem cells in the  
745 mammalian central nervous system. *Cell Research* (2009). doi:10.1038/cr.2009.56
- 746 26. Hughes, E. G., Kang, S. H., Fukaya, M. & Bergles, D. E. Oligodendrocyte progenitors  
747 balance growth with self-repulsion to achieve homeostasis in the adult brain. *Nat.*  
748 *Neurosci.* (2013). doi:10.1038/nn.3390
- 749 27. Hawrylycz, M. J. *et al.* An anatomically comprehensive atlas of the adult human brain  
750 transcriptome. *Nature* (2012). doi:10.1038/nature11405
- 751 28. Seidlitz, J. *et al.* Transcriptomic and Cellular Decoding of Regional Brain Vulnerability to  
752 Neurodevelopmental Disorders. *bioRxiv* (2019). doi:10.1101/573279
- 753 29. Tejada Neyra, M. A. *et al.* Voxel-wise radiogenomic mapping of tumor location with key  
754 molecular alterations in patients with glioma. *Neuro. Oncol.* (2018).  
755 doi:10.1093/neuonc/noy134
- 756 30. Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and molecular  
757 epidemiology of adult diffuse glioma. *Nat. Rev. Neurol.* **15**, (2019).
- 758 31. Reifenberger, G., Wirsching, H. G., Knobbe-Thomsen, C. B. & Weller, M. Advances in  
759 the molecular genetics of gliomas-implications for classification and therapy. *Nature*  
760 *Reviews Clinical Oncology* (2017). doi:10.1038/nrclinonc.2016.204
- 761 32. Thomas Yeo, B. T. *et al.* The organization of the human cerebral cortex estimated by  
762 intrinsic functional connectivity. *J. Neurophysiol.* (2011). doi:10.1152/jn.00338.2011
- 763 33. Mufford, M. S. *et al.* Neuroimaging genomics in psychiatry-a translational approach.  
764 *Genome Medicine* (2017). doi:10.1186/s13073-017-0496-z
- 765 34. Henderson, M. X. *et al.* Spread of  $\alpha$ -synuclein pathology through the brain connectome is  
766 modulated by selective vulnerability and predicted by network analysis. *Nat. Neurosci.*  
767 (2019). doi:10.1038/s41593-019-0457-5
- 768 35. Zhou, J., Gennatas, E. D., Kramer, J. H., Miller, B. L. & Seeley, W. W. Predicting  
769 Regional Neurodegeneration from the Healthy Brain Functional Connectome. *Neuron*  
770 (2012). doi:10.1016/j.neuron.2012.03.004
- 771 36. Brown, J. A. *et al.* Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain  
772 Atrophy. *Neuron* (2019). doi:10.1016/j.neuron.2019.08.037
- 773 37. Pedersen, P. -H *et al.* Migratory patterns of lac-z transfected human glioma cells in the rat  
774 brain. *Int. J. Cancer* (1995). doi:10.1002/ijc.2910620620
- 775 38. Venkatesh, H. S. *et al.* Electrical and synaptic integration of glioma into neural circuits.  
776 *Nature* (2019). doi:10.1038/s41586-019-1563-y
- 777 39. Mesulam, M. M. Fifty years of disconnection syndromes and the Geschwind legacy. *Brain*

- 778 (2015). doi:10.1093/brain/awv198
- 779 40. Buckner, R. L. & Krienen, F. M. The evolution of distributed association networks in the  
780 human brain. *Trends in Cognitive Sciences* (2013). doi:10.1016/j.tics.2013.09.017
- 781 41. van den Heuvel, M. P. *et al.* Evolutionary modifications in human brain connectivity  
782 associated with schizophrenia. *Brain* (2019). doi:10.1093/brain/awz330
- 783 42. Wei, Y. *et al.* Genetic mapping and evolutionary analysis of human-expanded cognitive  
784 networks. *Nat. Commun.* (2019). doi:10.1038/s41467-019-12764-8
- 785 43. Puchalski, R. B. *et al.* An anatomic transcriptional atlas of human glioblastoma. *Science*  
786 (80-. ). (2018). doi:10.1126/science.aaf2666
- 787 44. Lee, J. H. *et al.* Human glioblastoma arises from subventricular zone cells with low-level  
788 driver mutations. *Nature* (2018). doi:10.1038/s41586-018-0389-3
- 789 45. Shoshan, Y. *et al.* Expression of oligodendrocyte progenitor cell antigens by gliomas:  
790 Implications for the histogenesis of brain tumors. *Proc. Natl. Acad. Sci. U. S. A.* (1999).  
791 doi:10.1073/pnas.96.18.10361
- 792 46. Verhaak, R. G. W. *et al.* Integrated Genomic Analysis Identifies Clinically Relevant  
793 Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR,  
794 and NF1. *Cancer Cell* (2010). doi:10.1016/j.ccr.2009.12.020
- 795 47. Kondo, T. & Raff, M. Oligodendrocyte precursor cells reprogrammed to become  
796 multipotential CNS stem cells. *Science* (80-. ). (2000). doi:10.1126/science.289.5485.1754
- 797 48. Liu, C. *et al.* Mosaic analysis with double markers reveals tumor cell of origin in glioma.  
798 *Cell* (2011). doi:10.1016/j.cell.2011.06.014
- 799 49. Lake, B. B. *et al.* Integrative single-cell analysis of transcriptional and epigenetic states in  
800 the human adult brain. *Nat. Biotechnol.* (2018). doi:10.1038/nbt.4038
- 801 50. Mukherjee, S. The Emperor of All Maladies: A Biography of Cancer. *J. Postgrad. Med.*  
802 *Educ. Res.* (2012). doi:10.5005/jp-journals-10028-1025
- 803 51. Tang, J., He, D., Yang, P., He, J. & Zhang, Y. Genome-wide expression profiling of  
804 glioblastoma using a large combined cohort. *Sci. Rep.* (2018). doi:10.1038/s41598-018-  
805 33323-z
- 806 52. McLendon, R. *et al.* Comprehensive genomic characterization defines human  
807 glioblastoma genes and core pathways. *Nature* (2008). doi:10.1038/nature07385
- 808 53. Suzuki, H. *et al.* Mutational landscape and clonal architecture in grade II and III gliomas.  
809 *Nat. Genet.* (2015). doi:10.1038/ng.3273
- 810 54. Menze, B. H. *et al.* The Multimodal Brain Tumor Image Segmentation Benchmark  
811 (BRATS). *IEEE Trans. Med. Imaging* (2015). doi:10.1109/TMI.2014.2377694
- 812 55. Bakas, S. *et al.* Advancing The Cancer Genome Atlas glioma MRI collections with expert  
813 segmentation labels and radiomic features. *Sci. Data* (2017). doi:10.1038/sdata.2017.117
- 814 56. Bakas, S. *et al.* Identifying the Best Machine Learning Algorithms for Brain Tumor  
815 Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS  
816 Challenge. *arXiv* (2018).
- 817 57. Rohlfing, T., Zahr, N. M., Sullivan, E. V. & Pfefferbaum, A. The SRI24 multichannel  
818 atlas of normal adult human brain structure. *Hum. Brain Mapp.* (2010).  
819 doi:10.1002/hbm.20906
- 820 58. Avants, B. B., Tustison, N. & Song, G. Advanced Normalization Tools (ANTs). *Insight J.*  
821 1–35 (2009). doi:http://hdl.handle.net/10380/3113
- 822 59. Larjavaara, S. *et al.* Incidence of gliomas by anatomic location. *Neuro. Oncol.* (2007).  
823 doi:10.1215/15228517-2007-016




- 824 60. Romero-Garcia, R., Atienza, M., Clemmensen, L. H. & Cantero, J. L. Effects of network  
825 resolution on topological properties of human neocortex. *Neuroimage* (2012).  
826 doi:10.1016/j.neuroimage.2011.10.086
- 827 61. Alexander-Bloch, A., Raznahan, A., Bullmore, E. & Giedd, J. The convergence of  
828 maturational change and structural covariance in human cortical networks. *J. Neurosci.*  
829 (2013). doi:10.1523/JNEUROSCI.3554-12.2013
- 830 62. Vandekar, S. N. *et al.* Topologically dissociable patterns of development of the human  
831 cerebral cortex. *J. Neurosci.* (2015). doi:10.1523/JNEUROSCI.3628-14.2015
- 832 63. Alexander-Bloch, A. F. *et al.* On testing for spatial correspondence between maps of  
833 human brain structure and function. *Neuroimage* (2018).  
834 doi:10.1016/j.neuroimage.2018.05.070
- 835 64. Váša, F. *et al.* Adolescent tuning of association cortex in human structural brain networks.  
836 *Cereb. Cortex* (2018). doi:10.1093/cercor/bhx249
- 837 65. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective  
838 epidemiological study. *Nat. Neurosci.* (2016). doi:10.1038/nn.4393
- 839 66. Alfaro-Almagro, F. *et al.* Image processing and Quality Control for the first 10,000 brain  
840 imaging datasets from UK Biobank. *Neuroimage* (2018).  
841 doi:10.1016/j.neuroimage.2017.10.034
- 842 67. Smith, S. M., Hyvärinen, A., Varoquaux, G., Miller, K. L. & Beckmann, C. F. Group-  
843 PCA for very large fMRI datasets. *Neuroimage* (2014).  
844 doi:10.1016/j.neuroimage.2014.07.051
- 845 68. Rubinov, M. & Sporns, O. Complex network measures of brain connectivity: Uses and  
846 interpretations. *Neuroimage* **52**, 1059–1069 (2010).
- 847 69. Romero-Garcia, R. *et al.* Structural covariance networks are coupled to expression of  
848 genes enriched in supragranular layers of the human cortex. *Neuroimage* (2018).  
849 doi:10.1016/j.neuroimage.2017.12.060
- 850 70. Romero-Garcia, R. *et al.* Schizotypy-related magnetization of cortex in healthy  
851 adolescence is co-located with expression of schizophrenia-related genes. *Biol. Psychiatry*  
852 (2019). doi:10.1016/j.biopsych.2019.12.005
- 853 71. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. Revigo summarizes and visualizes long  
854 lists of gene ontology terms. *PLoS One* (2011). doi:10.1371/journal.pone.0021800

855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867

| Predictor | Beta Value | Standard Error | T Statistic | Percent Explained | Spin Test Corrected P |
|-----------|------------|----------------|-------------|-------------------|-----------------------|
|-----------|------------|----------------|-------------|-------------------|-----------------------|

|                         |         |        |          | <b>Variance</b> | <b>Value</b> |
|-------------------------|---------|--------|----------|-----------------|--------------|
| <b>Intercept</b>        | 3.2e-16 | 0.0499 | 6.37e-15 | NA              | NA           |
| <b>Nodal strength</b>   | 0.202   | 0.0543 | 3.72     | 7.86%           | 0.0010       |
| <b>OPC distribution</b> | 0.206   | 0.0566 | 3.64     | 7.58%           | 0.0040       |
| <b>PLS1 Loadings</b>    | 0.210   | 0.0594 | 3.54     | 7.17%           | 0.0052       |
| <b>PLS2 Loadings</b>    | 0.480   | 0.0577 | 8.32     | 29.9%           | 0            |


868 Table 1. Results of multiple linear regression model predicting tumor frequency.  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897



898  
899

900 **Figure 1. Non-random spatial distribution of gliomas.** A. Tumor frequency map derived from  
901 lesion masks from 335 patients with high- and low- grade glioma. B. Glioma frequency by  
902 common anatomic subdivisions. C. Glioma frequency represented at a parcel-level. Internal  
903 replicability of glioma frequency tested by constructing two independent maps from even splits  
904 of the cohort, where the first comprised of ~34% low-grade gliomas and the other of ~11%  
905 low-grade gliomas.


906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923



924  
925

926 **Figure 2. Gliomas localize to connector hubs of the brain.** A. Violin plot comparing glioma  
927 frequency distributions across canonical subnetworks. B. Histogram comparing glioma  
928 frequency distribution across primary versus association cortex. C. Functional connectome  
929 calculated from resting state functional scans of over 4000 UK BioBank participants. Nodes in  
930 the network are organized according to their affiliation with different canonical subnetworks. D.  
931 Correlations between glioma frequency and hub measures calculated from the functional  
932 connectome. E. Visualization of glioma frequency and functional hub measures on the cortical  
933 surface.


934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951



952  
 953 **Figure 3. Gliomas localize to brain regions enriched with stem-like cells.** A. Visualization of  
 954 the parcel masks representing the hippocampus and caudate superimposed on the mirrored tumor  
 955 frequency map. B. Average tumor frequency across the hippocampus and caudate (represented as  
 956 the dotted black line) compared to a distribution of average tumor frequency across 10000 sets of  
 957 two randomly chosen parcels. C. Co-expression among genes within the OPC gene list compared  
 958 to co-expression among 10000 identically-sized sets of genes. D. Correlation between OPC  
 959 distribution across cortex and glioma frequency ( $\rho = 0.45$ ;  $P_{\text{spin}} = 0.0001$ ). E. Visualization of  
 960 glioma frequency and OPC distribution on the cortical surface.


961  
 962  
 963  
 964  
 965  
 966  
 967  
 968  
 969  
 970  
 971  
 972  
 973  
 974  
 975  
 976  
 977  
 978  
 979





980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998

**Figure 4. Transcriptomic correlates of glioma frequency.** A. Alignment of AHBA sample locations to the tumor frequency map. B. Illustrative flowchart of the statistical analysis relating normative spatial gene expression patterns to glioma frequency. C. Gene ontology terms associated with two partial least squares components (PLS1 and PLS2) that related gene expression with glioma frequency. D. Median rank of 13 genes commonly altered in glioma compared to null distribution of median ranks. E. AHBA samples plotted by PLS1 loadings, PLS2 loadings, and cortex versus subcortex. F. Visualization of glioma frequency, PLS1 loadings, and PLS2 loadings on the cortical surface. PLS loadings from samples were assigned to parcels via a nearest neighbor mapping.



999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025

**Figure 5. Multiple linear regression model relating connectomic, cellular, and transcriptomic factors with glioma distribution.** A. Schematic of the multiple linear regression model. Intercept and error terms are not displayed. B. Fitted values and residuals of glioma distribution model. C. Scatter plot of predicted versus observed tumor frequency values. D. Percent of variance explained by each individual predictor of tumor frequency. These values were calculated using the partial correlation coefficient between each measure and tumor frequency.

1026 Genetic, Cellular, and Connectomic Characterization of Adult Human  
1027 Brain Regions Commonly Plagued by Glioma

1028

1029

Supplemental Information

1030

1031 Ayan S. Mandal<sup>1\*</sup>, Rafael Romero-Garcia<sup>1</sup>, Michael G. Hart<sup>1,2</sup>, John Suckling<sup>1</sup>

1032

1033 <sup>1</sup>Brain Mapping Unit, Department of Psychiatry, University of Cambridge

1034

1035 <sup>2</sup>Academic Division of Neurosurgery, Department of Clinical Neurosciences, University of  
1036 Cambridge

1037

1038

1039 \* Correspondence to: Ayan Mandal, University of Cambridge, Department of Psychiatry,  
1040 Herchel Smith Building, Robinson Way, Cambridge, UK CB2 0SZ, Email: [asm82@cam.ac.uk](mailto:asm82@cam.ac.uk)

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

## 1072 **Supplementary Methods**

1073

### 1074 *Spin Test Methodology*

1075

1076 The “spin test” involves comparing the observed inter-parcel correlation between maps of two  
1077 measures with a distribution of the correlations calculated after one of these maps has been  
1078 spatially permuted in a way that preserves contiguity between brain regions. Spatial permutation  
1079 was accomplished by projecting the centroid coordinates for each parcel onto an inflation of the  
1080 pial surface as a sphere<sup>1</sup>, applying a random rotation to that sphere, and then projecting the new  
1081 coordinates back onto the pial surface and assigning them to the nearest centroid coordinates of  
1082 the original parcellation. The result is a shuffled parcellation where most parcels remain  
1083 contiguous.

1084 Past studies using the spin test have focused on comparisons between cortical brain maps.  
1085 However, subcortical regions were also of interest in this study. Subcortical regions cannot be  
1086 projected onto the inflated spherical pial surface, so an alternative approach was needed. We  
1087 incorporated the subcortex into our null models by shuffling the eight subcortical regions with  
1088 respect to one another, whereas the cortical regions were shuffled using the spin test.

1089 After each spin permutation, two correlations were calculated; one between measures  
1090 estimated from parcels in their original configuration and the other in its permuted configuration,  
1091 and vice versa. These two correlations were averaged to form one of the 10000 values forming a  
1092 null distribution to which the observed correlation was compared to determine statistical  
1093 significance, as the proportion of null correlations greater than the observed correlation (i.e.  
1094  $P_{\text{spin}}$ ).

1095

### 1096 *AHBA Preprocessing*

1097

1098 Custom microarrays were used to measure the expression of all genes in the genome in 3702  
1099 brain sample locations across cortex, subcortex, and cerebellum<sup>2</sup>. Pre-processing of these data  
1100 followed a similar pipeline to previous work from our group<sup>3,4</sup>. Microarray probes were mapped  
1101 to genes using the genome assembly hg19 (UCSC GenomeBrowser;  
1102 <http://sourceforge.net/projects/reannotator/>)<sup>5</sup>. In line with criteria from Richiardi and colleagues  
1103<sup>6</sup>, probes were matched to a gene only if there were less than three mismatches between the  
1104 probe and reference sequence. When a gene matched with multiple probes, the probe with the  
1105 highest average expression across samples was selected to represent the expression patterns of  
1106 that gene. A recent study demonstrated the effectiveness of this preprocessing step in increasing  
1107 the correspondence between microarray and RNA-seq expression<sup>7</sup>. In total, the expression  
1108 patterns of 20647 genes across each sample location were evaluated. Samples which were  
1109 collected from the brain stem and cerebellum were excluded from the analysis, leading to a final  
1110 number of 2748 samples.

1111

1112

1113

1114

1115

1116

1117

1118 **Supplementary Results**

1119

1120 *Replication of main findings*

1121

1122 To determine the robustness of the results, major findings were internally replicated by using  
1123 sub-cohorts of patients with varying proportions of high- and low-grade glioma (Group 1 and  
1124 Group 2). Similar to the connectomic results from the full cohort, glioma frequency derived from  
1125 Group 1 was associated with nodal strength ( $\rho = 0.37$ ;  $P_{\text{spin}} = 0.00025$ ), betweenness centrality  
1126 ( $\rho = 0.48$ ;  $P_{\text{spin}} = 0.0002$ ), and participation coefficient ( $\rho = 0.34$ ;  $P_{\text{spin}} = 0.0042$ ), but not Z-  
1127 score modularity ( $\rho = 0.033$ ;  $P_{\text{spin}} = 0.33$ ), while glioma frequency derived from Group 2 was  
1128 associated with nodal strength ( $\rho = 0.29$ ;  $P_{\text{spin}} = 0.00033$ ), betweenness centrality ( $\rho = 0.51$ ;  
1129  $P_{\text{spin}} = 0.0002$ ), and participation coefficient ( $\rho = 0.25$ ;  $P_{\text{spin}} = 0.027$ ), but not Z-score  
1130 modularity ( $\rho = 0.072$ ;  $P_{\text{spin}} = 0.19$ ). The association between OPC distribution and glioma  
1131 frequency was also internally replicated: Group 1:  $\rho = 0.41$ ;  $P_{\text{spin}} = 0.0005$ ; Group 2:  $\rho =$   
1132  $0.46$ ;  $P_{\text{spin}} = 0.0001$ . Finally, PLS1 and PLS2 genes lists from the full cohort correlated with gene  
1133 lists from Group 1 at  $\rho = 0.991$  and  $\rho = 0.989$  respectively, and with Group 2 at  $\rho = 0.992$   
1134 and  $\rho = 0.990$ . PLS1 and PLS2 gene lists from Group 1 and Group 2 correlated with one  
1135 another at  $\rho = 0.967$  and  $\rho = 0.958$ .

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163



| <b>Parcel Names</b>           | <b>% Tumor Frequency</b> | <b>Parcel Names (cont.)</b>    | <b>% Tumor Frequency (cont.)</b> |
|-------------------------------|--------------------------|--------------------------------|----------------------------------|
| Thalamus-Proper               | 3.7                      | pericalcarine_part3            | 0.0                              |
| Caudate                       | 8.5                      | postcentral_part1              | 0.9                              |
| Putamen                       | 8.8                      | postcentral_part2              | 6.9                              |
| Pallidum                      | 6.5                      | postcentral_part3              | 1.6                              |
| Hippocampus                   | 9.0                      | postcentral_part4              | 2.6                              |
| Amygdala                      | 8.5                      | postcentral_part5              | 2.8                              |
| Accumbens-area                | 4.9                      | postcentral_part6              | 1.8                              |
| VentralDC                     | 2.7                      | postcentral_part7              | 1.7                              |
| bankssts_part1                | 8.0                      | postcentral_part8              | 1.9                              |
| bankssts_part2                | 12.5                     | posteriorcingulate_part1       | 3.5                              |
| caudalanteriorcingulate_part1 | 10.8                     | posteriorcingulate_part2       | 4.0                              |
| caudalmiddlefrontal_part1     | 6.0                      | precentral_part1               | 1.3                              |
| caudalmiddlefrontal_part2     | 6.1                      | precentral_part2               | 6.3                              |
| caudalmiddlefrontal_part3     | 3.3                      | precentral_part3               | 1.1                              |
| caudalmiddlefrontal_part4     | 4.3                      | precentral_part4               | 4.3                              |
| cuneus_part1                  | 0.1                      | precentral_part5               | 1.4                              |
| cuneus_part2                  | 1.5                      | precentral_part6               | 3.4                              |
| cuneus_part3                  | 0.3                      | precentral_part7               | 2.4                              |
| entorhinal_part1              | 6.7                      | precentral_part8               | 2.5                              |
| fusiform_part1                | 4.2                      | precentral_part9               | 3.5                              |
| fusiform_part2                | 6.3                      | precuneus_part1                | 2.2                              |
| fusiform_part3                | 1.0                      | precuneus_part2                | 3.9                              |
| fusiform_part4                | 9.4                      | precuneus_part3                | 4.4                              |
| fusiform_part5                | 3.4                      | precuneus_part4                | 2.1                              |
| fusiform_part6                | 6.8                      | precuneus_part5                | 3.3                              |
| inferiorparietal_part1        | 2.6                      | precuneus_part6                | 2.3                              |
| inferiorparietal_part2        | 8.1                      | precuneus_part7                | 3.7                              |
| inferiorparietal_part3        | 3.8                      | rostralanteriorcingulate_part1 | 7.5                              |
| inferiorparietal_part4        | 6.4                      | rostralmiddlefrontal_part1     | 5.0                              |
| inferiorparietal_part5        | 4.4                      | rostralmiddlefrontal_part2     | 5.3                              |
| inferiorparietal_part6        | 4.2                      | rostralmiddlefrontal_part3     | 2.3                              |
| inferiorparietal_part7        | 4.4                      | rostralmiddlefrontal_part4     | 5.9                              |
| inferiorparietal_part8        | 3.3                      | rostralmiddlefrontal_part5     | 3.6                              |
| inferiorparietal_part9        | 3.6                      | rostralmiddlefrontal_part6     | 6.0                              |
| inferiortemporal_part1        | 5.2                      | rostralmiddlefrontal_part7     | 4.6                              |
| inferiortemporal_part2        | 3.5                      | rostralmiddlefrontal_part8     | 7.3                              |
| inferiortemporal_part3        | 8.4                      | rostralmiddlefrontal_part9     | 5.1                              |
| inferiortemporal_part4        | 7.7                      | rostralmiddlefrontal_part10    | 5.5                              |
| inferiortemporal_part5        | 4.3                      | rostralmiddlefrontal_part11    | 5.4                              |
| inferiortemporal_part6        | 5.9                      | superiorfrontal_part1          | 1.5                              |
| isthmuscingulate_part1        | 2.7                      | superiorfrontal_part2          | 2.9                              |
| isthmuscingulate_part2        | 4.3                      | superiorfrontal_part3          | 3.1                              |


|                            |      |                          |      |
|----------------------------|------|--------------------------|------|
| lateraloccipital_part1     | 1.4  | superiorfrontal_part4    | 4.0  |
| lateraloccipital_part2     | 4.7  | superiorfrontal_part5    | 2.4  |
| lateraloccipital_part3     | 3.2  | superiorfrontal_part6    | 6.6  |
| lateraloccipital_part4     | 0.3  | superiorfrontal_part7    | 3.0  |
| lateraloccipital_part5     | 0.8  | superiorfrontal_part8    | 7.9  |
| lateraloccipital_part6     | 2.7  | superiorfrontal_part9    | 4.5  |
| lateraloccipital_part7     | 1.2  | superiorfrontal_part10   | 5.2  |
| lateraloccipital_part8     | 0.3  | superiorfrontal_part11   | 4.8  |
| lateraloccipital_part9     | 0.8  | superiorfrontal_part12   | 6.1  |
| lateralorbitofrontal_part1 | 3.3  | superiorfrontal_part13   | 6.1  |
| lateralorbitofrontal_part2 | 3.7  | superiorparietal_part1   | 2.7  |
| lateralorbitofrontal_part3 | 5.0  | superiorparietal_part2   | 3.3  |
| lateralorbitofrontal_part4 | 3.3  | superiorparietal_part3   | 5.7  |
| lateralorbitofrontal_part5 | 6.6  | superiorparietal_part4   | 2.8  |
| lingual_part1              | 2.5  | superiorparietal_part5   | 0.7  |
| lingual_part2              | 0.0  | superiorparietal_part6   | 1.7  |
| lingual_part3              | 2.1  | superiorparietal_part7   | 5.4  |
| lingual_part4              | 0.0  | superiorparietal_part8   | 3.5  |
| lingual_part5              | 1.4  | superiorparietal_part9   | 9.1  |
| lingual_part6              | 0.1  | superiorparietal_part10  | 6.3  |
| medialorbitofrontal_part1  | 2.7  | superiortemporal_part1   | 6.9  |
| medialorbitofrontal_part2  | 3.8  | superiortemporal_part2   | 7.1  |
| medialorbitofrontal_part3  | 2.3  | superiortemporal_part3   | 6.2  |
| medialorbitofrontal_part4  | 4.1  | superiortemporal_part4   | 8.5  |
| middletemporal_part1       | 4.1  | superiortemporal_part5   | 9.4  |
| middletemporal_part2       | 5.1  | superiortemporal_part6   | 12.5 |
| middletemporal_part3       | 6.5  | superiortemporal_part7   | 13.0 |
| middletemporal_part4       | 10.9 | supramarginal_part1      | 9.4  |
| middletemporal_part5       | 8.4  | supramarginal_part2      | 6.0  |
| middletemporal_part6       | 9.0  | supramarginal_part3      | 5.9  |
| parahippocampal_part1      | 7.1  | supramarginal_part4      | 1.8  |
| paracentral_part1          | 0.7  | supramarginal_part5      | 3.2  |
| paracentral_part2          | 3.4  | supramarginal_part6      | 2.4  |
| paracentral_part3          | 0.9  | supramarginal_part7      | 2.9  |
| parsopercularis_part1      | 3.6  | frontalpole_part1        | 1.4  |
| parsopercularis_part2      | 7.1  | temporalpole_part1       | 4.5  |
| parsopercularis_part3      | 7.1  | transversetemporal_part1 | 12.5 |
| parsorbitalis_part1        | 2.9  | insula_part1             | 11.7 |
| parstriangularis_part1     | 3.6  | insula_part2             | 10.0 |
| parstriangularis_part2     | 6.8  | insula_part3             | 11.5 |
| pericalcarine_part1        | 0.2  | insula_part4             | 12.7 |
| pericalcarine_part2        | 1.3  |                          |      |

1164  
1165  
1166

Supplementary Table 1. **Tumor frequency percentage values at each parcel.**


| <b>Glioma-related genes</b> |                |
|-----------------------------|----------------|
| <i>IDH1</i>                 | <i>TP53</i>    |
| <i>IDH2</i>                 | <i>NF1</i>     |
| <i>TERT</i>                 | <i>MDM2</i>    |
| <i>ATRX</i>                 | <i>PIK3CA</i>  |
| <i>EGFR</i>                 | <i>FUBP1</i>   |
| <i>CDKN2A</i>               | <i>NOTCH1</i>  |
| <i>CDKN2B</i>               | <i>PDGFRA1</i> |
| <i>PTEN</i>                 | <i>RIS</i>     |
| <i>RIK</i>                  | <i>PI3K</i>    |

1167  
1168 Table 2. **List of glioma-related genes tested for enrichment among transcriptomic correlates**  
1169 **of glioma distribution.** These genes were selected from a recent review of molecular genetic  
1170 markers of adult glioma subtypes<sup>8</sup>.  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187



1188  
1189 **Supplementary Figure 1. Raw lesion overlap map.** Colors indicate the number of lesions (out of  
1190 a total of 335) overlapping with the associated voxel.  
1191


1192  
1193  
1194  
1195  
1196



1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217

Supplementary Figure 2. **Rank correlations between nodal strength and other graph theoretical metrics of hubness.** Graph theoretical metrics with a correlation higher than the dotted line ( $\rho=0.95$ ) were screened from further analyses. While this threshold was arbitrary, the same measures would be screened across a variety of similar thresholds.





1218  
1219

1220 **Supplementary Figure 3. PLS regression analyses relating gene expression with glioma**  
1221 **frequency.** A. Scree plot demonstrating percentage of variance explained by each subsequent  
1222 PLS component. B. Percentage of variance explained across 1000 null models where the  
1223 mapping of glioma frequency to gene expression is randomized, compared to the percent  
1224 explained variance in the observed model, indicated by the dotted line. C. Distribution of  
1225 bootstrapped Z statistics for each gene, corresponding to PLS1 and PLS2. Positive and negative  
1226 Bonferroni-corrected significance thresholds are indicated by the dotted lines. These thresholds  
1227 were not applied to the PLS gene lists.

1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255

1256 **References**

- 1257
- 1258 1. Fischl, B. FreeSurfer. *NeuroImage* (2012). doi:10.1016/j.neuroimage.2012.01.021
- 1259 2. Hawrylycz, M. J. *et al.* An anatomically comprehensive atlas of the adult human brain  
1260 transcriptome. *Nature* (2012). doi:10.1038/nature11405
- 1261 3. Romero-Garcia, R. *et al.* Structural covariance networks are coupled to expression of  
1262 genes enriched in supragranular layers of the human cortex. *Neuroimage* (2018).  
1263 doi:10.1016/j.neuroimage.2017.12.060
- 1264 4. Romero-Garcia, R. *et al.* Schizotypy-related magnetization of cortex in healthy  
1265 adolescence is co-located with expression of schizophrenia-related genes. *Biol. Psychiatry*  
1266 (2019). doi:10.1016/j.biopsych.2019.12.005
- 1267 5. Arloth, J., Bader, D. M., Röh, S. & Altmann, A. Re-Annotator: Annotation pipeline for  
1268 microarray probe sequences. *PLoS One* (2015). doi:10.1371/journal.pone.0139516
- 1269 6. Richiardi, J. *et al.* Correlated gene expression supports synchronous activity in brain  
1270 networks. *Science* (80-. ). (2015). doi:10.1126/science.1255905
- 1271 7. Arnatkevičiūtė, A., Fulcher, B. D. & Fornito, A. A practical guide to linking brain-wide  
1272 gene expression and neuroimaging data. *Neuroimage* (2019).  
1273 doi:10.1016/j.neuroimage.2019.01.011
- 1274 8. Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and molecular  
1275 epidemiology of adult diffuse glioma. *Nat. Rev. Neurol.* **15**, (2019).  
1276  
1277